Answers are grounded in this paper and cite their sources.
The rate of minimally invasive procedures, such as aesthetic facial filler procedures, has risen in recent years, especially in Latin America.1 Conversely, data regarding the frequency of complications of aesthetic facial filler procedures and their associated factors are scarce. Between January and March of 2021, we conducted a survey of Brazilian board-certified dermatologists who practice aesthetic facial filler procedures. The questionnaire requested the number of procedures performed, types of products, and details of complications for procedures they attended in the last year. This study received institutional review board approval [CAAE: 39139120.3.0000.5078 (CEP HC/UFG)] and conformed to the principles of the Declaration of Helsinki. One hundred sixty dermatologists from 19 Brazilian states completed the survey. The mean number of aesthetic facial filler procedures reported by the dermatologists was 7.4 per week, resulting in an estimated 47,360 procedures per year. Hyaluronic acid (100 percent), poly-l-lactic acid (51 percent), and calcium hydroxylapatite (47 percent) were the main fillers they reported using; the frequency of use of each brand is detailed in Supplementary Table 1 (see Table, Supplemental Digital Content 1, which shows frequency of the use of aesthetic facial fillers by brand reported by 160 Brazilian board-certified dermatologists, https://links.lww.com/PRS/E935). The dermatologists reported 1032 complications from aesthetic facial filler procedures in the last year (6.45 per year). Complications resulting from their own procedures (n = 196) accounted for 1.23 per year, or 0.41 percent (95 percent CI, 0.36 to 0.47 percent) of aesthetic facial filler procedures. There was a weak correlation between the number of aesthetic facial filler procedures performed and the frequency of complications (rho = 0.26; p < 0.01). Complications from aesthetic facial filler procedures performed by other physicians (n = 286) accounted for 1.79 per year, and those performed by nonphysicians (n = 550) accounted for 3.43 per year. The main complications reported occurred 1 month or more after the procedure, especially nodules (63 percent, 1.81 per year), persistent or intermittent edema (62 percent; 1.35 per year), and late-onset infection (25 percent, 0.41 per year). Acute complications, such as arterial occlusion (15 percent; 0.18 per year) and ulceration (8 percent; 0.11 per year), were less frequent. The factors most frequently associated with each type of complication are presented in Table 1. Excessive volume and inadequate technique were the main factors associated with edema, nodules, and late-onset infection. Viral infection was associated with intermittent edema and nodules. Table 1. - Main Factors Indicated by 160 Brazilian Board-Certified Dermatologists for Each Type of Complication Type of Complication No. % 95% CI Intermittent edema 99 Viral infections (flu/common cold) 78 79 70.7–86.8 Permanent filler 37 37 27.8–46.9 Inadequate injection technique 35 35 25.9–44.8 Allergic crisis (asthma/rhinitis) 33 33 24.1–42.6 Excessive volume 26 26 17.6–34.9 Emotional stress 18 18 10.6–25.8 Vaccination 12 12 5.7–18.6 Nodules 101 Inadequate technique 56 55 45.8–65.1 Excessive volume 32 32 22.6–40.8 Viral infections (flu/common cold) 28 28 19.0–36.5 Nonpermanent filler 22 22 13.7–29.8 Permanent filler 17 17 9.5–24.1 Emotional stress 7 7 2.0–11.9 Collagenosis 6 6 1.3–10.6 Late-onset infection 41 Inadequate disinfection 22 54 38.4–68.9 Inadequate injection technique 20 49 33.5–64.1 Permanent filler 13 32 17.5–45.9 Previous infection at the site 9 22 9.3–34.6 Excessive volume 7 17 5.6–28.6 Unknown 7 17 5.6–28.6 The frequencies of the reported complications according to each facial site are displayed in Table 2. Intermittent edema was associated with the tear trough (69 percent); nodules, with the lips (30 percent) and chin (10 percent); and infection, with the malar cheeks (66 percent). Table 2. - Frequency of Sites Associated with Complications from Aesthetic Facial Filler Procedures Reported by 160 Brazilian Board-Certified Dermatologists Edema (n = 99) Nodules (n = 101) Late-Onset Infection (n = 41) Malar cheeks 19 (19%) 37 (37%) 27 (66%)* Lips 13 (13%) 30 (30%)* 7 (17%) Tear trough 69 (70%)* 22 (22%) 1 (2%) Nose 0 (–) 1 (1%) 2 (5%)* Chin 3 (3%) 10 (10%)* 2 (5%) Mandibular line 0 (–) 5 (5%) 3 (7%) Forehead 1 (1%) 1 (1%) 0 (–) *p < 0.05. Hyaluronic acid was the filler associated with intermittent edema (>40 percent) and vascular occlusion (>30 percent). Poly-l-lactic acid and hyaluronic acid were associated with nodules (>18 percent). Late-onset infection was associated with polymethyl methacrylate, despite the absence of its use by the dermatologists surveyed. The frequency of complications by brand is presented in Supplementary Table 2 (see Table, Supplemental Digital Content 2, which shows the frequency of the brands associated with complications from aesthetic facial filler procedures reported by 160 Brazilian board-certified dermatologists, https://links.lww.com/PRS/E936). There is a growing rate of unskilled nonmedical professionals performing aesthetic facial filler procedures, as well as an increasing volume injected per session, new classes of products, and the repetition of these procedures at the same site, all of which can facilitate the emergence of complications.1,2 Although adverse effects occur with all types of fillers, their incidence varies among brands due to several reasons, such as cross-linking, fermentation bioprocesses, and particle characteristics (size, surface, and load).3–5 In conclusion, complications of aesthetic facial filler procedures are mostly associated with unskilled professionals and inadequate technique. The rate of complications of specific brands should be assessed through targeted studies, especially regarding the technology of each manufacturer. DISCLOSURE Dr. Ianhez has worked as a speaker for Abbvie, Sanofi-Genzyme, Leopharma, Janssen, Biolab, Galderma, Theraskin, Novartis, FQM, and Vichy. Dr. Souza has no conflict of interest to declare. Dr. Miot has developed research and worked as speaker for Merz, Vichy, La Roche Posay, Eucerin, Abbvie, Theraskin, and Pierre-Fabre. No funding was received for this article. Mayra Ianhez, M.D., Ph.D.Marcela B. Souza, M.D.Department of DermatologyUniversidade Federal de GoiásGoiânia, Goiás, Brazil Hélio A. Miot, M.D., Ph.D.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: